Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | +1.83% | +0.04% | +12.97% |
13/03 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
13/03 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.97% | 8.84Cr | |
+5.12% | 11TCr | |
+11.62% | 11TCr | |
-0.26% | 2.23TCr | |
-11.79% | 2.21TCr | |
-7.89% | 1.87TCr | |
-38.36% | 1.76TCr | |
-9.95% | 1.69TCr | |
+4.77% | 1.38TCr | |
+36.30% | 1.25TCr |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform